Zhitong Finance App News, Saito Biotech (300583.SZ) announced that Shandong Sirui Pharmaceutical Co., Ltd., the holding subsidiary of the company, recently received the “Chemical Ingredient Marketing Application Approval Notice” for fluticasone furoate issued by the State Drug Administration. Fluticasone furoate is a potent glucocorticoid used in nasal spray to treat seasonal and perennial allergic rhinitis between 2 and 2 years of age; used for inhalation powder to treat asthma and chronic obstructive pulmonary disease (COPD).

The company's chemical ingredient fluticasone furoate obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”, indicating that the API has met relevant national drug evaluation technical standards. This approval will further enrich the company's product line and help enhance the company's market competitiveness in the field of chemical raw materials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.